Amicus Therapeutics, Inc. (FOLD) financial statements (2022 and earlier)

Company profile

Business Address 3675 MARKET STREET
PHILADELPHIA, PA 19104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:482483453504359330
Cash and cash equivalents2451631438049187
Short-term investments237320310424310 
Other undisclosed cash, cash equivalents, and short-term investments     143
Receivables5347332291
Inventory, net of allowances, customer advances and progress billings272014853
Inventory272014853
Other undisclosed current assets35302017195
Total current assets:597579520551392340
Noncurrent Assets
Operating lease, right-of-use asset212333
Property, plant and equipment42444811910
Intangible assets, net (including goodwill)221221221221221684
Goodwill198198198198198198
Intangible assets, net (excluding goodwill)2323232323487
Other noncurrent assets241928752
Total noncurrent assets:308307330239235697
TOTAL ASSETS:9058878507906271,037
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9897120815441
Accounts payable2217227813
Accrued liabilities18131611148
Employee-related liabilities242327222010
Taxes payable6117   
Interest and dividends payable  440 
Other undisclosed accounts payable and accrued liabilities283345371210
Debt  7   
Business combination, contingent consideration, liability199  856
Other undisclosed current liabilities292416814
Total current liabilities:1461301298670111
Noncurrent Liabilities
Long-term debt and lease obligation4346203322164154
Long-term debt, excluding current maturities  150322164154
Operating lease, liability434654
Liabilities, other than long-term debt1328332326391
Deferred compensation liability, classified     2
Deferred tax liabilities, net 6174
Deferred income tax liabilities555
Other liabilities765322
Business combination, contingent consideration, liability117232017214
Other undisclosed noncurrent liabilities395397917  
Total noncurrent liabilities:452470245361190545
Total liabilities:598600374447260656
Stockholders' equity
Stockholders' equity attributable to parent307286476343353360
Common stock333221
Additional paid in capital2,5952,3092,2271,7401,4011,120
Accumulated other comprehensive income (loss)5830(2)2
Accumulated deficit(2,296)(2,045)(1,769)(1,412)(1,064)(780)
Warrants and rights outstanding01212131616
Total stockholders' equity:307286476343353360
Other undisclosed liabilities and equity    1420
TOTAL LIABILITIES AND EQUITY:9058878507906271,037

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues30626118291375
Revenue, net375
Cost of revenue
(Cost of Goods and Services Sold)
(34)(31)(22)(14)(6)(1)
Gross profit:27123016077314
Operating expenses(477)(477)(464)(406)(473)(186)
Operating loss:(206)(247)(304)(329)(442)(182)
Nonoperating income (expense)(2)28210(5)
Investment income, nonoperating1310104 
Foreign currency transaction loss, before tax   (3)  
Other nonoperating income (expense)(3)(1)(3)(6)6(5)
Interest and debt expense(33)(30)(59)(22)(17)(5)
Loss from continuing operations before equity method investments, income taxes:(242)(274)(356)(349)(449)(192)
Other undisclosed loss from continuing operations before income taxes     (12)
Loss from continuing operations before income taxes:(242)(274)(356)(349)(449)(204)
Income tax expense (benefit)(9)(3)(0)01654
Net loss available to common stockholders, diluted:(250)(277)(356)(349)(284)(200)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(250)(277)(356)(349)(284)(200)
Other comprehensive income (loss) 0(0)  (1)
Comprehensive loss:(250)(277)(357)(349)(284)(201)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)533(4)3
Comprehensive loss, net of tax, attributable to parent:(254)(271)(354)(346)(288)(198)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: